Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167236 | 0.72 | HRH4 (0.43) | HRH4ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL606055 | 0.68 | HRH4 (0.54) | HRH4HRH3KCNH2HRH1 | |
| SCHEMBL2166427 | 0.68 | HRH4 (0.43) | HRH4HRH3 | |
| SCHEMBL21199977 | 0.66 | ALOX5AP (0.42) | ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL27907556 | 0.66 | HSD17B10 (0.41) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL21965412 | 0.64 | BPTF (0.48) | HRH4HRH3ALDH1A1LMNAMAPT | |
| SCHEMBL2801938 | 0.64 | HRH4 (0.52) | HRH4HRH3TDP1 | |
| SCHEMBL28395841 | 0.64 | HSD17B10 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL23123592 | 0.63 | HRH3 (0.39) | HRH4HRH3KCNH2SLC6A2SLC6A4 | |
| SCHEMBL10492501 | 0.63 | HSD17B10 (0.46) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008060766-A2 | HISTAMINE H4 RECEPTOR LIGANDS FOR USE IN PAIN TREATMENT | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885ALDH1A1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.